UA112962C2 - СТИМУЛЯТОРИ рГЦ АБО АКТИВАТОРИ рГЦ ОКРЕМО ТА У КОМБІНАЦІЇ З ФДЕ5 ІНГІБІТОРАМИ ДЛЯ ЛІКУВАННЯ КІСТОЗНОГО ФІБРОЗУ - Google Patents

СТИМУЛЯТОРИ рГЦ АБО АКТИВАТОРИ рГЦ ОКРЕМО ТА У КОМБІНАЦІЇ З ФДЕ5 ІНГІБІТОРАМИ ДЛЯ ЛІКУВАННЯ КІСТОЗНОГО ФІБРОЗУ

Info

Publication number
UA112962C2
UA112962C2 UAA201210468A UAA201210468A UA112962C2 UA 112962 C2 UA112962 C2 UA 112962C2 UA A201210468 A UAA201210468 A UA A201210468A UA A201210468 A UAA201210468 A UA A201210468A UA 112962 C2 UA112962 C2 UA 112962C2
Authority
UA
Ukraine
Prior art keywords
rgc
activators
treatment
combination
cystic fibrosis
Prior art date
Application number
UAA201210468A
Other languages
English (en)
Inventor
Петер Занднер
Дегенфельд Георгес Фон
Йоханнес-Петер Шташ
Original Assignee
Адверіо Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA112962(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Адверіо Фарма Гмбх filed Critical Адверіо Фарма Гмбх
Publication of UA112962C2 publication Critical patent/UA112962C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)

Abstract

Представлений винахід стосується розчинної гуанілатциклази (рГЦ) та фосфодіестерази (ФДЕ), фармакології стимуляторів рГЦ, активаторів рГЦ та ФДЕ інгібіторів. Більш конкретно, винахід стосується використання стимуляторів рГЦ і активаторів рГЦ у комбінації з ФДЕ5 інгібіторами для одержання медикаментів для лікування кістозного фіброзу (КФ).
UAA201210468A 2010-02-05 2011-03-02 СТИМУЛЯТОРИ рГЦ АБО АКТИВАТОРИ рГЦ ОКРЕМО ТА У КОМБІНАЦІЇ З ФДЕ5 ІНГІБІТОРАМИ ДЛЯ ЛІКУВАННЯ КІСТОЗНОГО ФІБРОЗУ UA112962C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05
PCT/EP2011/051532 WO2011095534A1 (en) 2010-02-05 2011-02-03 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Publications (1)

Publication Number Publication Date
UA112962C2 true UA112962C2 (uk) 2016-11-25

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201210468A UA112962C2 (uk) 2010-02-05 2011-03-02 СТИМУЛЯТОРИ рГЦ АБО АКТИВАТОРИ рГЦ ОКРЕМО ТА У КОМБІНАЦІЇ З ФДЕ5 ІНГІБІТОРАМИ ДЛЯ ЛІКУВАННЯ КІСТОЗНОГО ФІБРОЗУ

Country Status (33)

Country Link
US (1) US20130035340A1 (uk)
EP (1) EP2531187B1 (uk)
JP (2) JP6143461B2 (uk)
KR (1) KR101793304B1 (uk)
CN (3) CN102770133A (uk)
AU (1) AU2011212521B2 (uk)
BR (1) BR112012019666A2 (uk)
CA (1) CA2788969C (uk)
CL (1) CL2012002173A1 (uk)
CR (1) CR20120408A (uk)
CY (1) CY1116878T1 (uk)
DK (1) DK2531187T3 (uk)
EA (1) EA025177B1 (uk)
ES (1) ES2548394T3 (uk)
HK (1) HK1212892A1 (uk)
HR (1) HRP20151187T1 (uk)
HU (1) HUE028008T2 (uk)
IL (1) IL221012B (uk)
MA (1) MA33984B1 (uk)
MX (1) MX342944B (uk)
MY (2) MY159697A (uk)
NZ (1) NZ601612A (uk)
PH (1) PH12012501587A1 (uk)
PL (1) PL2531187T3 (uk)
PT (1) PT2531187E (uk)
RS (1) RS54336B1 (uk)
SG (1) SG182819A1 (uk)
SI (1) SI2531187T1 (uk)
SM (1) SMT201500286B (uk)
TN (1) TN2012000397A1 (uk)
UA (1) UA112962C2 (uk)
WO (1) WO2011095534A1 (uk)
ZA (1) ZA201205532B (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101793304B1 (ko) * 2010-02-05 2017-11-02 아드베리오 파마 게엠베하 낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
EP2585055A1 (de) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
NZ703989A (en) * 2012-09-07 2017-04-28 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
WO2016014463A1 (en) 2014-07-22 2016-01-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2017103888A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
WO2018112149A1 (en) 2016-12-16 2018-06-21 Cystic Fibrosis Foundaton Therapeutics Inc. Bycyclic heteroaryl derivatives as cftr potentiators
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
WO2024097316A1 (en) 2022-11-04 2024-05-10 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating systemic sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2009068652A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR101793304B1 (ko) * 2010-02-05 2017-11-02 아드베리오 파마 게엠베하 낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제

Also Published As

Publication number Publication date
AU2011212521B2 (en) 2015-11-19
EP2531187A1 (en) 2012-12-12
HRP20151187T1 (hr) 2015-12-04
CA2788969C (en) 2017-11-21
MA33984B1 (fr) 2013-02-01
JP2016155857A (ja) 2016-09-01
PT2531187E (pt) 2015-10-20
HUE028008T2 (en) 2016-11-28
JP6270907B2 (ja) 2018-01-31
EA201290702A1 (ru) 2013-02-28
JP2013518851A (ja) 2013-05-23
CL2012002173A1 (es) 2013-05-17
ES2548394T3 (es) 2015-10-16
SI2531187T1 (sl) 2016-01-29
PH12012501587A1 (en) 2020-10-19
KR20120125276A (ko) 2012-11-14
JP6143461B2 (ja) 2017-06-07
BR112012019666A2 (pt) 2017-06-20
WO2011095534A1 (en) 2011-08-11
EP2531187B1 (en) 2015-08-12
IL221012A0 (en) 2012-09-24
CN102770133A (zh) 2012-11-07
EA025177B1 (ru) 2016-11-30
CA2788969A1 (en) 2011-08-11
NZ601612A (en) 2014-08-29
TN2012000397A1 (en) 2014-01-30
MY160856A (en) 2017-03-31
AU2011212521A1 (en) 2012-08-16
MY159697A (en) 2017-01-13
CR20120408A (es) 2013-02-12
CN107929271A (zh) 2018-04-20
US20130035340A1 (en) 2013-02-07
CY1116878T1 (el) 2017-04-05
HK1212892A1 (zh) 2016-06-24
ZA201205532B (en) 2014-12-23
PL2531187T3 (pl) 2016-01-29
CN104800219A (zh) 2015-07-29
SG182819A1 (en) 2012-09-27
SMT201500286B (it) 2016-01-08
MX2012009011A (es) 2012-09-07
MX342944B (es) 2016-10-18
DK2531187T3 (en) 2015-11-09
KR101793304B1 (ko) 2017-11-02
IL221012B (en) 2018-01-31
RS54336B1 (sr) 2016-02-29

Similar Documents

Publication Publication Date Title
EA201290702A1 (ru) СТИМУЛЯТОРЫ sGC ИЛИ АКТИВАТОРЫ sGC, ПРИМЕНЯЕМЫЕ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРАМИ PDE5
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
EA201170942A1 (ru) СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX2014000635A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak.
UA114531C2 (uk) Противірусні сполуки проти rsv
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
PH12012500355A1 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
MX340607B (es) Moduladores de la fosfodiesterasa 10 (pde 10).
GB201014391D0 (en) Drug composition and its use in therapy
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
TR201309037A2 (tr) Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
MX2010006227A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
HK1172905A (en) Pyrazole derivatives as jak inhibitors